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Cancer is often used as a broad term to describe over 277 variant types of the disease. 
The progress of which is thought to be due to genetic changes (Hasspour & Dehghani 
2017). Research showed fundamental key characteristics that defined how cancer 
cells behave. These were condensed into eight key traits summarised as self-
sufficiency from growth signals, insensitivity to growth signal factors, evading 
apoptosis, limitless replicative ability, continuous angiogenesis, metastatic activity, 
escaping the immune response and reprogramming metabolism. Apoptosis is a 
mechanism that triggers a cellular programme leading to cell death. There are two 
main modes of apoptosis, the extrinsic and the intrinsic signal transduction pathways.  
The extrinsic pathway, triggered by death ligands such as TRAIL, contains many 
proteins such as death receptors and eventually culminates in Caspase-8 and -10 
initiating a downstream caspase cascade. There are however other proteins such as 
FLIP that can inhibit apoptosis triggered by death ligands. As FLIP is often 
overexpressed in cancer cells, compounds that can block its anti-apoptotic effect hold 
great promise. In this study a new inhibitor of FLIP was tested alone and in combination 
with TRAIL. Cell survival was measured with a Crystal Violet assay after treatment with 
FLIPi alone, recombinant TRAIL alone or a combination. Apoptosis was measured 
using a DNA hypodiploidy (Nicoletti) assay It was found that that cancer cells showed 
some cytotoxicity in response to the FLIPi, but the FLIP inhibitor did not induce 
apoptosis. Some cancer cells, such as colorectal cancer HCT116 cells and advanced 





others could not. The molecular reasons for this heterogeneity must be elucidated 
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cIAP Cellular inhibitors of apoptosis  
CRC Colorectal cancer 
DED Death effector domains 
DISC Death inducing signalling complex 
DR Death receptor 
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The term cancer is often used as a broad term to articulate over 277 variant types of 
the disease. The evolution of cancer is thought to be down to genetic changes such 
as chromosomal translocations, point mutations, deletions, gene amplification and 
activation of gene insertions (Hasspour & Dehghani 2017). 
Previous research ascertained fundamental processes that defined how cancer cells 
behaved.  These were summarised into 8 key behaviours. Self-sufficiency from growth 
signals, insensitivity to growth signal factors, evading apoptosis, replicative ability 
becoming limitless, sustained angiogenesis, metastatic activity, tissue invasion, 
evading the immune response and reprogramming metabolism (Fouad and Aanei 
2017). 
Cancer cells oppose healthy functioning cells in the way homeostasis is regulated. 
Deviant signalling, mutations, gene amplification and faulty degradation machinery can 
all be implicated in growth signals and cell death evasion by cancer cells. Many issues 
however are seen -but require more research- within downstream signalling pathways 
for example when the RAS protein contains mutations a multitude of issues arises in 
the affected cells. Proteins involved with regulatory functions and other activated 
pathways then consequently produce effects that thoroughly encapsulate enhanced 
growth, enhanced proliferation and apoptotic activity suppression. Proliferation is also 
encouraged when check points in the cell cycle are interrupted. An infamous example 





responsible for preventing any proliferation and then instigating repair for cells that can 
be salvaged, but cell death is the consequence for cells that are beyond repair. 
Understanding the biological mechanisms that underpin different cancer types will 
allow more efficient treatment and consequently better patient prognosis. In this 
project, the hallmark of apoptosis, evasion was studied in several different types of 
cancer by examining the role of the anti-apoptotic protein cFLIP with the help of a 
chemical inhibitor.  
1.2 Prostate cancer 
1.2.1 Pathophysiology  
Prostate cancer occurs in the prostate gland usually stirring in the outer gland cells of 
the prostate- referred to as acinar adenocarcinomas. This is the most common type, 
however there are 3 other types with significant occurrence. Ductal adenocarcinoma 
originates in the cells that line the prostate gland ducts, comparatively to acinar 
adenocarcinomas the spread is more rapid. Another type starts in the cells that line 
the urethra generally called transitional cell cancer but sometimes referred to as 
urothelial cancer. Most commonly transitional cell cancer migrates to the urethra from 
the bladder, but it can also do the opposite and migrate from the prostate into the 
bladder on rare occasions. The cells that cover the prostate can also become 
cancerous. These are the squamous cells and for that reason it is named squamous 
cell cancer. This type of prostate cancer spreads and proliferates more rapidly than 





scale is used. Several biopsies of the tumour are taken and studied, each sample being 
graded between 1 and 5, with 5 being the cells are very abnormal and 1-2 being healthy 
‘normal’ prostate cells these scores are then added together. Furthermore, the 
Gleason scale can elucidate glandular differentiation. Grade 1 describes carcinomas 
with a uniform, oval and medium sized glands but are seen to be well differentiated 
amongst normal tissue. Grade 2 is very similar the former but differs in the glandular 
presentation. In this grade the glands are less well defined than that of the previous 
grade and vary more in shape and size. Grade 3 starts to deviate from grades 1 and 2 
more significantly, the glands take on a twisted, angular and irregular form. (Humphrey, 
2004). 
1.2.2 Diagnosis  
The Tumour, Node, Metastasis method can also be used to characterise the tumour 
progression. Stage 1 within this method would suggest the tumour is contained to half 
of the prostate gland or less. Comparatively stage 2 is when the tumour has spread 
through more than one half of the prostate gland but is still encapsulated within the 
gland. When the cancer cells have ruptured through the capsule of the prostate gland 
it is said to be stage 3 once the tumour moves beyond this point it has usually 
metastasised in to surrounding areas such as the back passage and bladder; this is 
stage 4. Stage 4 can also include metastasis into the lymph nodes and/or other organs 
beyond the immediate area e.g. lungs. (Borley and Feneley, 2009). Within developed 
countries prostate cancer is the second biggest cause of deaths in men, with incidence 





and so more men will have the disease. This will show as a lag in the data as it is 
collated and analysed. There are several risk factors that are strongly associated with 
prostate cancer, the foremost is age. Incidence is low under the age of 40 after which 
the likelihood increases exponentially. Other factors such as diet have been linked, 
with low levels of vitamin E, Vitamin D and selenium being taken in from the diet. High 
dietary intake of saturated fats has also been seen to increase the incidence. 95% of 
prostate cancers are not hereditary. The 5% that is hereditary can face a further 
increase in risk if it is the male in the family line has been affected. If the affected 
individual is the father the risk is increased by 1.3, if the individual is a brother the risk 
is increased by 2.5. Prostate cancer seems to arise when there are at least 8 
mutational events. The initial event in the timeline is the loss of tumour suppressor 
genes, one of the most common is the p53 gene. Investigation showed the p53 gene 
to have been mutated in 64% of cancerous growths. The genes of p21 and p73 have 
also shown mutations when investigated in tumours, with the former having found to 
be mutated in 55% of tumours. The recently recognised p73 has been found have a 
high degree of homology to p53 and has some mutations when explored in prostate 
cancer. Tumour suppressor gene p10 has been characterised as one of the genes that 
is most mutated in prostate cancer and because of this is credited with the acquisition 
of the metastatic phenotype in individuals. Many of the different prostate tumour types 
evolve from the cells in the urethra previously mentioned called the transitional 
epithelium. These tumours also result from cells in ducts with both types leading to 
transitional cell carcinomas. These make up about 4% of the prostate cases. As 





cancer tumours (Mazhar and Waxman, 2002). Prostate cancer is characteristic for 
being initially asymptomatic. It is often diagnosed through a physical rectal examination 
and confirmed with a blood test. If the prostate is found to be cancerous it would feel 
rough at the edges opposed to a health gland being smooth, it would also usually have 
enlarged presentation with the latter giving rise to benign prostatic hyperplasia (BHP). 
Symptoms only start to occur at a late stage, BHP can cause symptoms such as 
frequent urination, a struggle to urinate and a small flow of urine.  Very occasionally 
blood can also be found in the urine, which is a condition known as haematuria and is 
often caused when the gland is eroded or infected. If the individual goes untreated the 
cancer can enter advanced stages. This can cause pain to occur in the perineum and 
cause other symptoms to emerge due metastasis of the cancer to different parts of the 
body. The symptoms can range from weight loss to neurological complaints (Patel and 
Klein 2009). 
There is one main problem associated with rectal examinations as a diagnostic 
method, this is the variation displayed by the medical professional assessing the 
patient. Prostate specific androgen testing (PSA) was then introduced with the first 
uses not for diagnosis but as tool to monitor prostate cancer progression. This method 
was popular as it allowed early detection. This was a massive advantage as the 
asymptomatic nature previously made early detection difficult. However, BHP can 
often present readings similar to that of an individual with prostate cancer leading to 







There are several treatment options available to patients, if the tumour has a low 
Gleason score (and is confined to the gland). ‘Watchful Waiting’ can be employed, the 
other strategy is radical surgery - removing the tumour by removing the prostate gland. 
The consequences of these treatment options result in an improved result for the 
individual. Comparatively if the Gleason score is high it corresponds with a later stage 
cancer. This often means the gland has ruptured and often metastasised into other 
areas. This consequently sees a poor outcome for the patient, however there are 
treatments that can be used to manage the cancer (Maitland and Collins, 2008). 
Firstly, androgen modulation therapy – also known as androgen withdrawal therapy- 
is quite effective in cancer of later stages however positive responses only last for 1.5-
2 years (Rocchi et al., 2004) These positive results include a decrease in PSA levels, 
a decrease in patient pain and a decrease in the size of the tumour. Cancerous tissue 
returning will give rise to symptoms returning and bone metastasis occurring, it also 
causes the androgen receptor mechanism to partially or completely breakdown. It 
allows the cells to survive and proliferate using mechanisms independent of the 
androgen signalling pathway (Rocchi et al., 2004). Initially the tumour recedes as a 
consequence of androgen ablation because androgens play a core role in cell 
proliferation and regulating apoptosis rates. When the anti-androgens are given as 
treatment it causes the levels of androgen to fall and thus lowering the rates of 





1.3 Colorectal cancer  
1.3.1 Pathophysiology 
Colorectal cancer (CRC) is thought to be the second most common cause of death 
linked to cancer within the US and the third most common overall. It is thought that 
over an individual’s lifespan the possibility of developing sporadic colorectal cancer is 
5%. It occurs in the epithelial cells that line the large intestinal tract. Normal cell 
processes are disrupted, and so cancerous characteristics start to develop, one of the 
first is the ability of autonomous growth. In this stage the capability to metastasize and 
damage surrounding cells has not yet developed. These characteristics are caused by 
epigenetic factor modifications. This then results in the gene function being altered. 
Detecting CRC at this stage has the biggest influence on positive outcomes for the 
affected individual.  
1.3.2 Diagnosis  
At present there are four main methods used to screen for CRC: the faecal occult blood 
test, sigmoidoscopy, a virtual colonoscopy and the immunological faecal occult blood 
test (Jimenez et al., 2010).  Similarly, to prostate cancer CRC can be categorised using 
the tumour-node-metastasis (TNM) method (Amin et al., 2017). This method was 
originally designed to allow a patient prognosis to be determined. It is now used to aid 
treatment plans and gain insight into how effectively a treatment is working.  TNM 
described the primary tumour location (T), whether there is lymph node involvement 





et al., 2017). Faecal occult blood tests look for blood in the faecal matter, this occurs 
because adenomas often bleed. When adenomas progress to higher stages, the 
epigenetic factors such as mutational events that cause this can be detected. This is 
done by using molecular techniques to amplify the DNA found in the blood that has 
been shed into the faeces. The DNA ends up in the stool occurs because of bacteria 
and normal exfoliation by the mucus in the colon and by cancerous tumours and 
polyps. A massive advantage of this method is that it does not take the patient any 
amount of time to prepare for the procedure however is rather expensive comparatively 
to other methods. 
 An endoscope can be used to examine a part of the colon where 2/3 of CRC are 
found, this is the sigmoid portion and the rectum. Both methods have seen to have a 
positive impact on the mortality of patients, this is due to the time sensitive nature of 
the disease. The earlier the diagnosis the more effective treatment usually is. However, 
sigmoidoscopy allows very small polyps to be detected. It also involves less labour 
time and is cheaper than the faecal blood test. The biggest drawback to sigmoidoscopy 
is that the entire colon is not visualized and so some tumours could be missed. As a 
result of a virtual colonoscopy a three (or two) dimensional is created with a high 
resolution. Using radiography, a thin sample section is used in combination with 
computed tomography.  This is beneficial comparatively to a traditional colonoscopy 








One of the most used treatments to combat CRC are fluoropyridines, more specifically 
fluorouracil. It acts through affecting the enzyme in pyrimidine nucleotide synthesis 
which effects the rate of synthesis. This affect occurs due to inhibition of thymidylate 
synthase. In order to augment the effect of fluorouracil it can be given in combination 
with leucovorin. It boosts the inhibition of DNA synthesis as the binding of fluorouracil 
to thymidylate synthase is stabilised. 
The structure of fluorouracil is very similar to that of uracil, which is one of the four 
bases in RNA. The difference in the two structures is that 5FU has a fluorine atom in 
place of a hydrogen atom on the C-5 as seen in figure 1. 5FU uses the same 
mechanism to transport it into the cell; facilitated transport (Zhang et al., 2008) 
 
 
Figure 1 The structure of 5-Flurouracil comparatively to the structure of uracil.  5-Flurouracil is an analogue of uracil, 






About 20% of Individuals with advanced stage disease that receive this treatment could 
see a reduction of up to 50% in the size of the tumour. Dependent on the delivery 
method the degree of adverse the side effects can vary. If the treatment is taken orally, 
digestive problems can arise, more specifically effects can be predicted based on a 
time dosing schedule. If patients receive doses continuously -usually for 4-5 days- toxic 
side effects such as Stomatitis and neutropenia can arise. This is inflammation of the 
mucous membranes in the mouth and a low level of white blood cells respectively.  
However, if these doses are administered weekly the patient is more likely to endure 
diarrhoea. If the treatment is given intravenously, palmar plantar erythrodysestheia can 
develop. In palmar plantar erythrodysestheia the hands and feet may swell and 
become red and painful. With this administration route there is a lesser gastrointestinal 
and haematologic toxic effect associated. Current FDA (food and drug administration) 
approved drug are Fluorouracil, Capecitabine, Irinotecan, Oxaliplatin, Cetuximab and 
Bevacizumab (Meyerhardt and Mayer, 2005). 
Once this occurs several active metabolites are produced intercellularly, 
fluorodeoxyuridine monophosphate, fluorodeoxyuridine triphosphate and fluorouridine 
triphosphate. These three metabolites disturb the process of thymidylate synthase 
(TS) and the synthesis of RNA. The enzyme dihydropyrimidine dehydrogenase 
catalyses the reaction and so is the limiting factor on the rate. It converts 5FU into 
dihydroflourouracil, when administered to a patient a majority (>80%) is catalysed in 
the liver. 5FU is activated once fluorouridiane monophosphate had been produced 





phosphoribosyltransferase. It does this using cofactor phosphoribosyl pyrophosphate. 
Secondly – which is a more indirect approach- it occurs through consecutive steps 
starting with flourouridine, phosphorylase with uridine kinase then being produced. 
Phosphorylation then converts flourouridiane monophosphate into fluorouridine 
diphosphate (Zhang et al., 2008). More metabolites are produced if flourouridiane 
diphosphate is phosphorylated further. More phosphorylation leads to the formation of 
flourouridine triphosphate, or fluorodeoxyuridine diphosphate can be formed by 
conversion using ribonucleotide reductase. Active metabolites can then be produced 
by the dephosphorylation or phosphorylation of fluorodeoxyuridine diphosphate. The 
metabolites produced are fluorodeoxyuridine monophosphate and fluorodeoxyuridine 
triphosphate correspondingly. Another activation pathway can occur which converts 
5FU to fluorodeoxyuridine catalysed thymidine phosphorylase. Fluorodeoxyuridine 
then undergoes phosphorylation via thymidine kinase to produce fluorodeoxyuridine 
monophosphate. 5FU is converted into dihydroflourouracil, which is carried out by 







Figure 2: a schematic depicting the way 5FU is metabolised and the main metabolites that are active, FUMP, FUDP 
and FUTP. 5FU is predominantly converted to FUMP directly by OPRT with cofactor PRPP. It is indirectly converted 
by FUR through UP and UK sequential behaviour. FUMP is phosphorylated to FUDP and then phosphorylated 
again to FUTP which is the active metabolite. This metabolite can also be changed to FdUTP via RR. 
Dephosphorylation would convert FdUDP to generate active metabolite FdUMP and phosphorylated to create 









1.3.4 Thymidylate synthase summary 
5,10-methylene tetrahydrofolate performs as methyl donor when deoxyuridine 
monophosphate is converted to deoxythymidine monophosphate. This produces 
fluorodeoxyuridine monophosphate, which is the active form of 5FU, which binds to 
the nucleotide site of TS. Produced from this reaction is a more stable ternary complex 
consisting of 5,10-methylene tetrahydrofolate and TS. This then prevents 
deoxythymidine monophosphate from contacting the nucleotide binding site on TS and 
consequently inhibiting the synthesis of deoxythymidine monophosphate. This 
subsequently causes an imbalance of deoxynuclotides and raises the levels of 
deoxyuridine triphosphate. The result of this is fatal DNA damage and the DNA repair 
and/or synthesis processes being impaired. The active form of 5FU and Deoxyuridine 
triphosphate get wrongly incorporated into the DNA. With these compounds being 
present in such high amounts, mechanisms to repair DNA, involving uracil-DNA-
glycosy-lase fail. The continuous repair attempts and incorporation of the active 5FU 
and deoxyuridine triphosphate lead to breaks in DNA strands and cell death.  
However colorectal cancer cells can develop a resistance to 5FU meaning that to re-
sensitise cells to 5FU a combination treatment could be employed. When 5FU is 
administered to the patients with advanced colorectal cancer there is a low response 
rate of 15%. The resistance to 5FU is largely attributed to rapid DNA repair and 
increased metabolizing of the drug. Specific resistance revolves around the TS 





gene and patients’ prognosis seems to be linked with the level of this gene expression. 
Patients that have a higher expression in tumour cells exhibit a poorer prognosis.   
More specifically 5FU is combined with platinum-based drugs such as oxaplatin and a 
folinic acid more specifically leucovorin. Oxaplatin is unique comparatively to other 
platinum-based drugs as it has a 1,2 – diaminocyclohexane ligand as part of its 
composition. The other platinum compounds combined with the previously mentioned 
ligand result in DNA repair processes to become heavily impeded. Although, 
resistance to oxaliplatin can occur and is linked the nucleotide repair pathway, a 
specific protein labelled WBSCR22 is also connected to resistance. The WBSCR22 
protein can be used as a biomarker and furthermore may be a focus for development 
of new therapies to bypass the rising resistance (Van der Jeught et al., 2018) 
1.4 Pancreatic cancer  
Pancreatic cancer has been reported to be the 7th most common cancer globally. For 
example in 2008, out of 280,000 new cases of pancreatic cancer 265,000 lead to 
death, showing the aggressive nature of the disease (Bosetti et al., 2012). 
This can be attributed to three main characteristics of pancreatic cancer 1) metastases 
in early stages comparatively to other cancers 2) the high morbidity rates are 
associated with both cachexia (muscle wastage), extreme weight loss, pain and low 
energy (asthenia) finally it is also resistant to most current treatments accommodating 
uncontrolled growth (Li et al., 2004). Worldwide it is the 14th most common cancer, with 





five-year survival rate and only 25% survive one year. Most cases are diagnosed at 
later stages of disease. This is mostly due to the symptoms that present being 
ambiguous and generic to many other conditions (Kleeff et al., 2016). 
1.4.1 Diagnosis 
However, some symptoms that present can be linked to tumours in specific locations 
within the pancreas. Tumours located in the head of the pancreas while small are often 
only discovered when jaundice occurs without feeling pain. Some individuals also 
report some back or abdominal pain. Symptoms if they arise usually occur due to 
surrounding structures and organs being compressed. If the tumour is located in the 
tail of the pancreas, symptoms such as pain on the left side of the abdomen can occur 
initially, although more often symptoms are related to metastatic growth (Li et al, 2004). 
Currently, there are few diagnostic tools and fewer which are very specific. Most 
treatment options revolve around palliative care with a small number of patients eligible 
for radical surgery, these eligible patients have localised tumours (Kleef at al., 2016).  
There are a few genetic mutations that present themselves within pancreatic cancer, 
these are KRAS, CDKN2A, SMAD4 and TP53. It may be difficult to produce new 
therapeutic routes as at an epigenetic and metabolic level, pancreatic cancer is rather 
complex. Furthermore, there are several pathways and protein interactions that get 
activated complicating matters further. The most common type of malignancy in this 
type of cancer is adenocarcinomas categorised as malignant neoplasms. More 





new cases in 2015. Rarer forms are neuroendocrine tumours and acinar carcinomas 
with the former often secreting hormones. Acinar carcinomas sometimes release 
digestive enzymes into the circulatory system. The most seldom seen cases are colloid 
carcinomas, solid-pseudopapillary neoplasm and pancreatoblastomas (Vincent et al., 
2011).  
1.4.2 Pathophysiology  
Suggested mechanisms producing cancers are the mutations and consequent 
inactivation of oncogenes and similar mechanisms with tumour suppressor genes. 
Growth factors also suffer from mutations that subsequently result in abnormal growth 
factors. Some growth factors and the relevant receptor have been found to effect signal 
transduction pathways for control and differentiation outcomes. Abnormalities that 
occur with mutations in these receptor pathways can lend a large advantage to the 
growth and survival of subsequent cancers. Many growth factors have been identified 
as being overexpressed -this included their receptors. cytokines, vascular endothelial 
growth factor and the family of epidermal growth factors are among those identified in 
this overexpression. Many hallmarks of cancer occur due to the copious amounts of 
factors promoting growth and the disruption of factors that inhibit growth. Commonly 
seen is the evasion of cell death, angiogenesis, metastasis and self-sufficiency from 
growth signals. These mechanisms have been elucidated quite well, for example 
hypoxia has been seen to manage the expression of vascular endothelial growth 
factor. Hypoxia is a common condition that arises when solid tumours occur, thus when 





tumour mass has been observed to cause changes in the extracellular pH leading to 
overexpression of vascular endothelial growth factor. Up-regulation of vascular growth 
factor and interleukin 8 operates through the acidosis and modulated by transcription 
factors NF-kB and AP-1 being transactivated. This deviant gene expression of proteins 
such as interleukin-1 that are involved when the cancer has metastasized, is the 
consequence of changes to the behaviour of transcriptional factors. There are two 
mechanisms put forward to explain this, of which the first is genetic alterations. These 
alterations occur on oncogenes genes such as K-ras and the outcome is continuous 
action in transcriptional factors. It is thought that this mechanism occurs in the initial 
stages of growth, with hypoxia and acidosis contributing in latter stages. Therefore, as 
growth continuous into advanced stages, tumour growth and development will become 
unrestrained and stress environments such as acidosis may increase seeing an 
increase in angiogenesis and metastasis.  Being able to elucidate and target some of 
this gene expression may lead to more therapeutic avenues being produced in the 
future (Li et al, 2004). 
1.5.3 Risk factors 
 There are several risk factors that are associated with pancreatic cancer. Age is seen 
to have a large impact on cases and consequently it is unusual to see a diagnosis of 
a patient under 30, with only 10% of individuals being under 55. It has been elucidated 
that reproductive factors do not impact incidence however more cases are seen in 
males over females. Different ethnicities seem to see different incidence rates. 





developing pancreatic cancer than Caucasian individuals. This could be attributed to 
other factors being linked more heavily to specific ethnicities. African- Americans may 
be found to be at a higher exposure to factors such a smoking and having higher 
incidence of diabetes. However, the biggest underlying cause of this variance could be 
attributed to other genetic interaction within the environments. Some studies have 
drawn a link between blood types and incidence. Some blood groups have a higher 
risk of adenocarcinoma of the pancreas developing. Blood groups O, A, B and AB carry 
the highest risk, this is thought to be a consequence of alterations in 
glycosyltransferase mechanisms. More specially those involved in the host 
inflammatory state across the mentioned groups (Rawla et al., 2019). 
It has recently been suggested that the gut microbiota may influence the risk of 
developing pancreatic cancer. The most feasible mechanism put forward is that of 
immune activation inflammation is a consequence and propagates the same 
inflammation seen induced by tumour development. Research by Memba et al (2017) 
found an association between the development of pancreatic cancer and lower levels 
of Neisseria elongate and streptococcus mitis.  Conversely when there were higher 
levels of porphyromonas gingivalis and Granulicatella adiacens the risk of cancer 
developing was increased.  
Pancreatic cancer can only be regarded as having a familial cause if ≥2 first degree 
relatives have been diagnosed, this describes a relatively small percentage of 5-10% 
of cases. However, if there is a genetic association, the individual is up to 9 times more 





risk increases by just over 3.5-fold (32-fold increase comparatively to no risk) if there 
are ≥3 first degree relatives affected. Individuals that have type 2 diabetes have been 
found to have a higher risk (McGuigan et al., 2018). 
 
Smoking is the factor that causes the greatest risk, rendering a positive correlation with 
the development of the disease. Analysis of many studies focused on the risk of 
smoking found that there was 74% higher risk for those that are current smokers and 
an increased risk of 20% for those individuals that no longer smoke. Once an individual 
has terminated smoking the risk doesn’t decrease for at least 10 years with some 
studies suggesting that it takes 20 years for the risk to return to the same level as an 
individual who has never smoked. The length of time spent smoking and the volume 
smoked has also been found to increase the probability of developing this disease. 
The influence of e-cigarettes has yet to be elucidated but they thought to contain less 
harmful additives than those in traditional smoking. (Iodice et al., 2008). Diet contains 
a risk, more specifically the amount of alcohol consumed in one’s diet. There is limited 
research related directly to the induction of pancreatic cancer by alcohol. However, the 
development of pancreatitis comes with an increased risk of pancreatic cancer 
evolving. Seen as the main cause of chronic pancreatitis is excessive alcohol intake 
alcohol can be loosely linked with the disease occurring (Samokhvalov et al., 2015). 
Pancreatitis is the resultant fibrosis and loss of both acinar and islet cells due to 
progressive inflammation of the pancreas. It is thought that in the US, between 1 and 





pancreatitis endured a 13-fold higher risk than those deemed as healthy or compared 
against a control group (McGuigan et al., 2018). Due to the amount of pancreatic 
cancer that arises from chronic pancreatitis this scenario could become a potential 
cancer screen. This is due to the low amount of chronic pancreatitis cases arising, 
however there is no current test, and a long period of time often elapses during which 
pancreatitis Is present, but cancer has not developed. Diet has been linked to cancer 
more specifically the consumption of red and processed meat. It is suggested that this 
is due to DNA damage caused. When this damage occurs carcinogens such as N-
nitroso compounds are produced. However, specifically regarding pancreatic cancer 
there is tenuous evidence to suggested causation (McGuigan et al., 2018).  
1.4.4 Diagnosis and staging  
Although most cases only present symptoms at advanced stages if there is suspicion 
a physical examination can be carried out. Sometimes in individuals that are presenting 
jaundice, the abdomen can become distended but painful at the gall bladder location.  
Traditional computational tomography is the main method used for initial visualization. 
The favoured method is a dual phase helical CT, this is due to the high level of 
sensitivity associated along with the non-invasive nature. It has a successful 
identification rate of 98% for metastatic tumours and pancreatic adenocarcinomas.  To 
provide a diagnosis for patients with tumours that are not viable for surgery, a fine 
needle aspiration biopsy can be completed using endoscopic ultrasonography to 
chaperon the procedure. This means that patients that are not suitable for surgical 





The previously mentioned -on page 2- Tumour, node, metastasis method can be 
applied to pancreatic cancer but when being assessed by clinician, tumours are 
categorised as resectable, metastatic and locally advanced. When described as 
unresectable it is due to the tumour metastasizing to other locations or arterial 
involvement e.g., the lymph nodes or invasion or inferior vena cava. In order to stage 
a patient accurately medical history and a physical examination are first considered. if 
this imaging is inconclusive the use of endoscopic ultrasonography can look for smaller 
tumours and elucidate vascular association. 
1.4.5 Treatment 
With respect to treatment the only possibility of somewhat curative action is surgery to 
remove the lesion, with the biggest limitation being very few cases being eligible. 
Surgery is performed according to the Whipple procedure, the head and uncinate parts 
of the pancreas, duodenum, proximinal 6 inches of the jejunum, gallbladder, common 
bile duct and distal stomach are removed. A surgical connection is then made between 
the common hepatic duct and the remainder of the pancreas and stomach joined to 
the jejunum. An alternative option to the is the pylorus-preserving pancreatic 
duodenostomy. The benefit of this procedure is that it offers the patient reduced blood 
loss and a shorter operating time. However, both carry similar risks: fistula of the 
pancreas, infection of the wound, delayed gastric emptying, anastomicleaking, 
haemorrhaging and endocrine insufficiency within the pancreas. If the cancer is in the 
body or the tail of the pancreas distal pancreatectomy is performed. As well as the 





nature that surrounds body and tail lesions occurring the viability for surgery is less 
than a half of cases involving head lesions. Once the cancer has progressed to a 
metastatic nature surgery is no longer viable, causing chemotherapies to be 
considered. Gemcitabine is commonly used as an initial therapy with a 12-month 
survival rate for patients offering a reduction or stability in symptoms such as patient 
weight and pain comparatively with another option of treatment- fluorouracil 
monotherapy. 
Figure 3: shows the areas affected by surgical treatment; the whipple procedure and the resultant system created. 










If the lesions are advanced in nature but are still localised external beam and 
intraoperative therapy can slow the progression for those patients not eligible for 
surgery. However, this method does not affect patient morbidity or the likelihood for 
metastasis to occur. Although there is the option of marrying the radiation therapy with 
fluorouracil-based treatment which comparatively with radiation alone, sees 40% of 
patients surviving 1 year. Another treatment option was pairing gemcitabine with 
radiation therapy, there is a rise in toxicity, yet it does not see a significant increase in 
survival when compared with a pairing with fluorouracil. After these options have been 
evaluated and exhausted, palliative care is applied (Freelove and Walling, 2006). 
1.5 Breast cancer  
Within the United Kingdom, breast cancer is the most commonly occurring malignancy 
is responsible for 18% of cancer found in women.  
1.5.1 Risk factors 
There are many risk factors associated with breast cancer and risk of disease 
development. As a woman ages the incidence will rise rather quickly, it is thought to 
be the most common cause of death for women between ages 40-50 (McPherson et 
al., 2000). Incidence is so connected with age, that for every decade a women risk will 
double until the menopause is reached. Most risk factors are connected to oestrogen, 
and it has been found when a female starts menstruating can affect the risk of 
developing cancer. The later in life menstruation starts the lower the risk of the disease 





menarche there is a 5% lower risk. Similarly, menopause can add a higher risk to 
women that experience it at a later age with each subsequent year increasing the risk 
by 3% (Key et al., 2001). It is thought that enduring the menopause carries a protective 
mechanism by reducing the rate of risk, so much so that postmenopausal females with 
the same comparative factors are at a lower risk than premenopausal. Females that 
are perimenopausal suffer from immediate risk of development. After a woman has 
given birth, they are initially at an increased risk however this does then see a 
reduction. Compared with those that have not given birth those that have, have a 25% 
decrease of risk. Adding to this it seems that the more births experienced the more 
protected a female is from risk culminating in a 50% decrease in those with 5 births 
behind them. There is a secondary risk factor which affects woman and childbirth 
independently of the number of births. The age of the female for the first birth can affect 
risk, the younger the individual the more reduced the risk. The risk associated with 
endogenous hormones has been examined and associated with serum oestradiol 
levels. The risk for postmenopausal women with raised serum levels carries 2 times of 
that of women with lower levels. When women take oral contraceptives that contain 
both progesterone and oestrogen the risk of developing breast cancer increases up to 
25%. This risk can be reduced once the pill is no longer taken although it takes up to 
10 years after cessation for no significant risk to be apparent. Localised cancers of the 
breast occur in the largest number, comparatively with cancers that develop beyond 
the breast tissues, when combined oral contraceptives are taken. It is considered that 
in countries that see populations ingesting high fat diets, breast cancer rates are 





intake of fat. Interestingly a difference has not been observed between the risk seen in 
vegetarians and those that consume meat (Key et al., 2001). It has postulated that 
when diets contain more phyto-oestrogens – food such a soya- may reduce risk by 
blocking the effect of endogenous oestrogens which are more potent in nature (Key et 
al., 1999). There has also been a slight increase in risk associated with alcohol 
ingestion. It has also been seen that high levels of ionizing radiation are universally 
damaging to tissue; however, breast tissue has been found to be particularly 
susceptible to the damaging effects. The risk of cancer developing has been mostly 
explored in women up to the age of 40 and the risk has been calculated at 1 Gy ranging 
from 1.1 to 2.7.  Information is still evolving however it is currently thought that there 
are at least five germ line mutations influencing the disease development. These are 
BRCA 1 & 2,P53, PTEN and ATM genes. BRCA 1 and 2 are infamous for causing high 
risk for breast cancer risk, ovarian cancer is also associated with these mutations. Li-
Fraumeni cancer syndrome can be more likely to develop when there are mutations in 
the p53 gene. Other childhood cancers can develop such as sarcoma, brain tumours 
and early onset breast cancers. Mutations in PTEN can also be the cause of Cowden’s 
disease, a cornerstone of this disease being the development of breast cancer. ATM 
is the fifth mutation that is thought of as high risk if there are mutated alleles. These 
germline mutations mentioned hold 20-25% of the risk among all breast cancers- that 
is within families that have had 4 or more cases of breast cancer these mutations would 
be involved. Furthermore, these mutations are thought to account for 5% of breast 
cancer cases throughout the population. A study in Iceland found that women that 





was reached. A different study of a population of Ashkenazi Jewish females in the US 
found that this rate was higher at 56% by the same age. (Key et al., 2001). 
1.5.2 Sub-Types 
The most common forms of breast cancer are ductal and lobular carcinomas, invasive 
in description and responsible for 75% and 15%, respectively (Honrado et al., 2005).   
Traditionally, classification is based on histological type and grade. Now divided into in 
situ -comprised of ductal and lobular- and invasive types. All invasive carcinomas are 
histologically graded. A score is awarded (1-3) according to 3 categories. Proportion 
of tubule formation, degree of nuclear pleomorphism and mitotic count. This cumulates 
to a total score, 3-5 results in grade 1. 6-7 a grade 2 and 8-9 results in a grade 3 
tumour. As with other types of tumours, staging is assigned according to the tumour-
node-metastasis method. High grade (grade 3) lobular carcinomas are produced from 
lower grade tumours. This is due to random mutations in TP53, HER2 and MYC genes. 
Luminal, basal-like, HER2 -positive and HER -normal like are subtypes of intrinsic 
breast cancer types. Luminal subtypes can also be further split into A and B types 
(Vuong et al., 2014). It is estimated that 5-10% of all breast cancer cases are hereditary 
and are heavily associated with the BRCA1 and BRCA2 genes. Families that have 
high rates of ovarian and breast cancers have a high rate of mutations in these genes 
of roughly 45%. These genes are important as the normal functions are involved in 
tumour suppression through controls on cell processes such as division and death.  





expression regulation and repair in response to DNA damage. Another role is that of 
maintaining the structure of the chromosome.  It is thought that cases of familial breast 
cancer differ to that of sporadic cases. The differences can be in morphological, 
molecular and immunophenotypic features. Invasive ductal carcinomas are more 
commonly seen in BRCA1 and 2 mutation carriers. BRCA1 mutations specifically, also 
carry a higher incidence of medullary carcinomas at 13%, whereas only 3% develop 
medullary carcinomas with BRCA2. The invasive ductal carcinomas carry a clear 
histotype, with projecting lymphocytic infiltrate, necrosis, pushing margins and 
numerous mitosis sites. An important note about tumours that arise from BRCA1 
mutations is the high histological grade- grade 3- that the tumours often present at. 
Comparatively, grade 2/3 is the most common staging for BRCA2 tumours. Is has also 
been shown that cases with BRCA1 mutations also show a high amount (73-90%) of 
oestrogen receptor negativity and low expression of progesterone receptor (Honrado 
et al., 2005).  
1.5.3 Diagnosis 
Most woman usually raise a medical appointment due to a lump being found in the 
breast or breast pain. The first assessment is a physical examination of the patient, 
along with familial history being considered. If symptoms are not being presented a 
mammography of the breast tissue is performed. It has been seen to increase survival 
incidence of woman if screening is done between 50-70 years old. Women in the 20-
39 age bracket will have a breast examination every 3 years, once 40 years old is 





Once a lump has been found ultrasonography can be used to distinguish mass 
characteristics, solid or cystic breast mass. This method is beneficial if the mass cannot 
be found when first using a mammogram. Digital mammography can be used in place 
of standard mammography as the image can be find tuned for better visibility. Biopsies 
of masse can be performed, there are three techniques being used. Fine needle 
aspiration, core biopsy and excisional biopsy. Fine needle is used for cytology 
samples, core biopsies remove the centre of the mass and if the likelihood of 
malignancy is high excision biopsy methods are used (Apantaku, 2000). 
1.5.4 Treatments 
The main treatment selections are cytotoxic compounds, surgery, radiation and 
endocrine drugs. The treatments are based on whether the case is of a primary cancer 
or is systemic in nature. Radiation therapy is usually used in conjunction with surgery, 
to get rid of any lingering cancerous cells.  Cytotoxic compounds are often used when 
the breast cancer is advanced, common drugs are docetaxel, 5FU and doxorubicin. 
Some HER-2 positive carcinomas are being treated with a monoclonal antibody that 
has been humanised for use called trastuzumab. A limitation of this therapy is the 
determining the patients genotype before application of treatment. Due to the evolving 
characteristics of breast cancer and the many different factors (such as age, receptors 







1.6 Apoptotic pathways 
1.6.1 Extrinsic pathway 
Apoptosis and necrosis are two mechanisms of cell death within the body. Apoptosis 
is programmed cell death, often by external or internal stimulus. Necrosis is only 
initiated when there is external damage (Ghobrial et al., 2005). Apoptosis is an 
imperative process to maintain cell tissue populations. It can also occur if there is 
damage to the cells or if an immune response had been triggered and consequently 
cells need to be destroyed. Apoptosis can be instigated due to both physiological and 
pathological factors. Often stimulus such as cell damage activates the p53 dependant 
pathway, otherwise known as the intrinsic pathway. Other cells use the extrinsic 
pathway, this is activated by ligand binding. The cells often express a Fas or TNF 
receptor and binding leads to cross linkage of proteins (Elmore, 2007).  
The extrinsic pathway contains many proteins such as death receptors, the membrane-
bound Fas ligand, the Fas complexes, the Fas-associated death domain, and 
caspases-8 and -10. Caspase-8 and 10 initiate a downstream caspase cascade. As 
previously introduced ligation of cell surface receptors is the starting point for this 
pathway. These receptors are referred to as death receptors. The TNF -tumour 
necrosis factor- receptor family is comprised of Fas, TRAIL (DR4), TNF R1, DR3 (Apo 
2), DR5 (TRAIL R2), and DR6.  
Immune surveillance of transformed or infected cells is heavily involved with Fas 





pathway is renowned for involvement in proliferative and inflammatory signalling as 
well as death related cell functions. Cell deaths activates the Fas ligand pathway, this 
causes Fas ligands that are membrane bound to associate with inactive Fas 
complexes consequently forming the death inducing signalling complex (DISC). This 
complex contains Fas-associated death domain protein along with caspase-8 and -10. 
Subsequently, activation of caspase-8 occurs this in turn causes a downstream 
caspase cascade.  Caspase-8 activation can induce cell death without having 
previously activated the caspase cascade. Cell death can also be a consequence of 
interactions with the intrinsic pathway. Proapoptotic Bid is cleaved and brings about a 
release of cytochrome-c. There are many proteins and pathways that regulate the 
extrinsic pathway. When these mediators become abnormal, malignancies can result. 
This is evidenced by  Landowski et al. (1997), mutations and deletions in Fas have 
been found in various hematologic malignancies. Transcription factors NFκB and 
activating protein 1 regulate the Fas ligand pathway. FAP-1, as-associated-death-
domain-protein like interleukin-1β-converting enzyme-like inhibitory protein and decoy 
receptors (often TRAIL receptor 3 and 4) also inhibit this pathway through antagonistic 
stimulation of competitive binding with the Fas ligand (Ghobrial et al., 2005).  
1.6.2 Intrinsic pathway  
Key regulators of apoptosis have been found to be overexpressed in many cancers, 
this has been found to be caused without chromosomal translocation mutations. Bcl-2 
proteins are key regulators of apoptosis, and this overexpression can lead to 





are in the G0 cell division checkpoint thus adding to resistance.  Conversely, this means 
if levels of Bcl-2 can be decreased, the apoptotic response of anticancer drugs can be 
stimulated.  
Bcl-2 proteins are made up of two subgroups: proapoptotic and antiapoptotic 
constituents. The antiapoptotic proteins block the release of cytochrome-c and 
therefore supress apoptotic action. Post-translational alteration occurs on proapoptotic 
proteins after receiving a death signal. These alterations are those such as 
dephosphorylation and cleavage. The cleavage results in activation and translocation 
of the proteins into the mitochondria subsequently initiating apoptosis. Cytochrome-c 
and second mitochondria derived activator of caspases- often known as IAP-binding 
protein- are released due to the outer mitochondrial membrane becoming permeable. 
This cytochrome is then in the cytosol which then associates with apoptotic protease 
activating factor 1 (Apaf-1). This causes the caspase cascade to begin, starting with 
caspase-9 followed by caspase-3. Once activated the caspases cause the nuclear 
lamin to become cleaved and the nucleus to breakdown due to the influence of 








Figure 4 schematic of apoptotic pathways: intrinsic and extrinsic and the events that follow initiation. TRAIL binding 
to cell surface death receptors triggers the extrinsic pathway to be activated. These receptors are only found on 










1.7 Tumour necrosis factor related apoptosis inducing ligand (TRAIL) 
1.7.1 TRAIL receptor activation 
TNF-related apoptosis-inducing ligand, commonly referred to as TRAIL can induce cell 
death by apoptosis in many different types of cells. TRAIL interacts with the death 
receptors on cells resulting in cell death. Interestingly this only occurs with transformed 
and tumour cells. The lack of interaction with normal cells saw TRAIL rise to a position 
of a potential cancer therapy (Griffith et al 1998).  
Many types of cancer have so called death receptors on the cell surface. TRAIL can 
activate the extrinsic pathway through ligation to the receptors, these are TRAIL-R1 
and TRAIL- R2 also known as death receptors 4 and 5. Although it initiates through 
ligation interactions, there are also cornerstones of intrinsic pathways that have been 
observed (Mellier et al., 2010).  
When TRAIL binds to the death receptors, clustering of the receptors occurs. This 
consequently causes the recruitment of Fas associated protein with death domain 
(FADD). The conscription of pro-caspase-8 follows and then forms the death 
inducing signalling complex due to the FADD adaptor protein. Pro-caspase 8 
instigates DISC activation and causes caspase-3, -6 and -7 to become cleaved. This 
cleavage produces membrane blebbing, fragments of DNA being created and 
nuclear shrinkage. In some events the intrinsic pathway is engaged via caspase-8 





1.7.2 TRAIL resistance and cFLIP 
TRAIL efficiency can be limited by the shortage of death receptors presenting on the 
cell surface.  
Cellular FLICE inhibitory protein (FLIP) has very close homology to that of caspase-8. 
This means it is preferentially recruited into the DISC as it binds to FADD, thusly 
activation of caspase-8 is inhibited, and the extrinsic pathway is not activated. If cFLIP 
is inhibited it is thought that cells can be re-sensitised to TRAIL. It is thought that TRAIL 
induced apoptosis is induced by cycloheximide of actinomycin (a transcription 
inhibitor).   
Increased cFLIP expression corelates with higher levels of TRAIL resistance, this can 
occur through post translational modifications and cFLIP degradation. There are two 
forms of cFLIP known and both can be engaged into the DISC complex. These are 
cFLIPs and cFLIPL, both contain death effector domains (DED), the main difference is 
that of the caspase like domain. cFLIPL contains one in contrast to the absence of the 
domain in the cFLIPs. However, cFLIPL lacks a cysteine residue which is responsible 
for catalytic activity. cFLIPL has been found in some cancers to be favourably drafted 
into the DISC (Wang et al., 2008). Resistance can also be increased by the cancer 
being driven towards a survival pathway. This happens when a secondary complex is 
formed after DISC formation. TNFR1-associated death domain (TRADD), IκB kinase, 
TNF receptor-associated factor 2 (TRAF2), receptor-interacting protein (RIP). Pro-
caspase-8, FADD and cFLIP form this complex and is liable non-apoptotic signals 





phosphoinositide 3-kinase (PI3K)/Akt), and mitogen-activated protein kinase (MAPK) 
pathways as seen in figure 4.  
To circumvent this resistance combination treatments are being employed. The intent 
to create a synergistic effect re-sensitising the cancer cells to TRAIL. These 
combination approaches act through stress to the endoplasmic reticulum. The creates 
an upregulation of the DR4 and DR5, resulting in apoptosis being increased due to 











Figure 5 a schematic of the structure of the variants of cFLIP splice variants and caspase 8, DEDs, cleavage and 
phosphorylation sites are shown. All variants contain DEDs that allow recruitment into the DISC. FLIP(L) has a pseudo-kinase 
domain that can be cleaved by procaspase-8 – which is bound in the DISC- forming cleavage products p43- and p12. The 
FLIP(L) pseudo-kinase domain contains a nuclear localization signal and nuclear export signal also. FLIP (S) and (R) do not 
possess the pseudo-caspase domain that FLIP(L) has. They also have different C terminus. The green variants show 
procaspase-8 structure dimerisation of procaspase-8 leads which leads to a cleavage in the catalytic domain resulting in a p12 




















Figure 6 schematic of the role FLIP in the apoptosis pathway, including the inhibition of procaspase-8 and -10 activation 
consequently preventing the caspase cascade. TRAIL can activate the extrinsic pathway through ligation to the 
receptors, these are TRAIL-R1 and TRAIL- R2 death receptors 4 and 5. TRAIL binds to the death receptors causing 
clustering of the receptors. The recruitment of Fas associated protein with death domain (FADD) follows. The 
conscription of pro-caspase-8 follows and then forms the death inducing signalling complex due to the FADD adaptor 





1.8 Aims and objectives  
A cFLIP inhibitor will be used followed by treatment with TRAIL. Apoptosis, proliferation 
and survival of the cancer cells during and after treatment will then need to be 
measured. Below are various methods that could be used to do this. 
With the previous information in mind, the aim is to investigate the effect of clip 
inhibitors on apoptosis and the application to aid in overcoming TRAIL resistance. 
1.9 Cell Lines used for the project 
1.9.1 Prostate cancer PC3, LNCap AND DU145  
Research showed that PC3 cells have some deleted segments on chromosome 1 
overlapping LCE3Band LCE3C genes. These genes are often deleted in roughly 18% 
of prostate tumours, however their role in adenocarcinoma tumorigenesis have not 
been elucidated (Cerami et al., 2012). The gene PTEN is also deleted; this deletion 
renowned for being a motivator of prostate cancer (Carver et al., 2011).  
When investigated by Seim et al. (2017) it was found that the LNCap cell line had a 
large number of stop gained events. These are changes that are usually resultant in 
nonsense mutations, non-functional proteins or sometimes reduced function in 
proteins. At amino acid location 318 of menin, a C into T mutation is found. This is a 
somatic inactivity mutation often found in endocrine cancers, hinting that menin acts 





 Tumour sensitive (TS) function via the P53 gene was seen in DU145. Expression of 
the P223L allele in PC3 confirmed the TS function of the gene. In DU145 cells 
methylation of p21Waf1 promoter is observed, and it has also been revealed that 
methylation of the p21Waf1 promoter occurs in PC3 and LNCaP cells as well. 
Activated p21Waf1 substantiated that P223L TS activity may have been influenced by 
cellular components/location. When cells have the temperature sensitive allele (at 
37C) the p53 protein takes on the mutant conformation, resulting in loss or gain of 
function and a lack of ability to transactivate genes (Bajgelman and Strauss, 2006).  
1.9.2 Colorectal cancer HCT116 
HCT cells see two regions that have homozygous loss rather closely; there is a 50 kb 
separation of the 25 and 50 kb deletions in the WWOX gene. It was identified that 
among the 3 chromosome 16 containing material locations, one had a translocation 
breakpoint. One such heterozygous deletion was that of exons 6-8. This causes allele 
specific expression, which would be responsible for any biological changes, this can 









1.9.3 Pancreatic PancTu1 
There are a few genes that are commonly associated with pancreatic cancer: KRAS, 
TP53, CDKN24 and SMAD4. These are oncogene and tumour suppressor genes 
respectively and are regarded as being the main drivers of this cancer type 
(Bazzichetto et al., 2020).  The region of 8p11-21 is a location that often has alterations 
in it when pancreatic cancer arises and contains many complex rearrangements, 
oncogenes and tumour suppressor genes. Upon further research it was found that 
there is a translocation breakpoint focused on the NRG1 gene at the previously 
mentioned location. NRG1 is thought to code for various forms of epidermal growth 
factor like ligand, this could promote cell growth and differentiation, together with 
breakpoints seen in the gene there is a strong implication it is involved with pancreatic 
oncogenesis (Adelaide et al., 2003). 
 
1.9.4 Breast cancer MDA-MB-231 
This cell line is associated with both high levels of mutated P53 and phospholipase 
activity. When there is a lack of growth factors phospholipase initiates a survival signal 
allowing growth, also supressing apoptotic signals when undergoing serum withdrawal 
(Hui et al., 2006). Strano et al. (2000) suggest that theses mutated p53 subdues 






2. Methods  
2.1 Materials 
All chemicals were purchased from sigma (St. Louis, MO), unless stated otherwise. 
Recombinant TRAIL (rTRAIL) was bought from R&D systems. The cFLIP inhibitor was 
generously provided by Professor Richard Clarkson, School of Biosciences, Cardiff 
University. 
2.2 Cell Culture 
The colorectal carcinoma cell line HCT116 was cultured in McCoy's 5A (Lonza). 
LNCaP, C4-2B, DU145 and PC3 prostate cancer cells were cultured in RPMI medium 
(Lonza). The breast cancer cell line MDA-MB-231 was cultured in DMEM (Lonza) and 
the pancreatic PancTu1 cancer cells were cultured in RPMI medium. All media were 
supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific), 100 U/ml 
penicillin and 100 μg/ml streptomycin. 
 
2.3 Crystal Violet assay 
Cell survival was measured after performing a crystal violet staining. Seven days after 
treatment with FLIPi alone, recombinant TRAIL alone or in combination with FLIPi, a 
Crystal Violet stain was added to paraform-aldehyde-fixed cells. The stain was then 





air-dry. Images were taken and for quantification the Crystal Violet was then extracted 
in 500 µl of methanol. The resulting samples were then analysed in a microplate reader 
to measure the absorbance at 490 nm to obtain quantitated cell survival values. 
2.4 Nicoletti assay  
Apoptosis was measured after carrying out a Nicoletti assay according to Riccardi and 
Nicoletti (2006). Treatments FLIPi alone, recombinant TRAIL alone or in combination 
with FLIPi. After 48 h after treatments with FLIPi alone, TRAIL alone or combinations 
of both agents, cell culture supernatants, trypsinised cells and PBS wash solutions 
were collected in one tube per sample and then centrifuged at 2,000 RPM for 5 
minutes. Subsequently, the supernatants were discarded, and the pelted cells were 
lysed and resuspended in 200 ml of Nicoletti buffer (50 mg/ml propidium iodide (PI), 
0.1% (w/v) sodium citrate, 0.1% (w/v) Triton X-100). The samples were measured in a 
BD Accuri C6 flow cytometer that detected the intensity of the PI fluorescence and 
analysed with the BD Accuri software. Each measurement was repeated three times. 
Apoptotic fragmentation is a key characteristic of apoptosis, this assay uses 
fluorogenic reagents (Nicoletti buffer) that bind stoichiometrically to the nucleic content. 
When a sample is analysed using a flow cytometer if there are any apoptotic cells 









3.1 Cell survival after cFLIP inhibitor treatment  
 cFLIP is involved in the apoptotic pathway and allows the cancer cells to avoid 
programmed cell death. This is a consequence of the inhibitory action of cFLIP on the 
caspase cascade initiation and thus allowing the cells to continue to survive and 
proliferate. cFLIP Therefore, the effects of a novel cFLIP inhibitor (FLIPi) on reducing 
cell growth in various cancer cell lines was investigated. First, the cytotoxic and 
apoptotic effects of the FLIPi on its own and in the second part in combination with 
TRAIL were examined. 
HCT116 is a mammalian colorectal cancer cell line, that is a standard and frequently 
used cell line of this cancer type. It is one of three strains of malignant cells isolated 
from a male with colonic carcinoma. They harbour a mutation in codon 13 of the KRAS 
proto-oncogene but are p53 wild type. In response to TRAIL, they are considered to 
be moderately sensitive. First, we carried out survival assays on HCT116 cells after 
treatment with FLIPi. For this we stained the cells with Crystal Violet and quantified the 
stain in untreated controls and cells treated with various concentrations of FLIPi. 
Compared to the untreated control the FLIPi showed cytotoxic effects even at the 
lowest concentration of 1.6 µM that increased in a dose-dependent manner and was 
most pronounced at the concentrations of 50 and 100 µM (Figure 5). At 100 µM the 





25% at 1.6 µM.  There was a large error observed at a FLIPi concentration of 6.25 µM, 
which indicates that further repeats are required. However, this does not change the 
overall outcome of the experiment. In summary, the FLIPi inhibitor exerts cytotoxic 





















Figure 7 Cell survival measured in HCT116 cells pre-treated with decreasing concentrations of FLIPi for 7 days before harvesting. The control 
for this assay is 0 µM of FLIPi with increasing concentrations thereafter. Crystal violet stain was used to visualise viable cells, each cell line was 





LNCaP cells are isolated from a from a male patient with lymph node metastatic 
prostate carcinoma and are androgen dependent. It is one of several prostate cell lines 
often used and often used to model this cancer type. This cell line is responsive to 5-
alpha-dihydrotestosterone but with respect to TRAIL is generally considered to be 
resistant. First, we carried out survival assays on LNCaP cells after treatment with 
FLIPi. This was done was done using crystal violet stain, using the control to quantify. 
Varying concentrations of FLIPi was then used to treat the cells.  Cytotoxic effects were 
shown by FLIPi at 100 µM as a single treatment, with an approximate 80% reduction 
in cell survival compared with 0 µM (figure 8). Some lower effects were seen at 50 and 
25 µM. In summary FLIPi exhibits cytotoxic effects at high concentrations of FLIPi but 
























Figure 8 Cell survival measured in LNCap cells treated with decreasing FLIPi concentrations, the control for this assay is 0 µM of FLIPi with increasing 
concentrations thereafter. Cells stained with crystal violet to visualise each cell line was repeated 3 times, with each sample in each assay also being tested 3 






C4-2B is an androgen-independent subline of LNCaP cells developed by co-
inoculation into an athymic male nude mouse with human fibroblasts which were 
derived from an osteosarcoma. There were no significant effects observed. However, 
some effect is seen with the 100 µM concentration comparatively with 0 µM with a 50% 
reduction in cell survival seen in 100 µM comparatively to that of the 0 µM (Figure 9). 
There is a decrease in cell growth with the 50 µM with approximately just over 50% in 
cell survival reduction comparatively to the 0 µM, an approximate 2% increase in cell 
survival reduction compared to with 100 µM. Figure 9 also demonstrates a dose curve 
for FLIPi in use with C4-2B cells, up to 6.25 µM. In summary this cell line has not been 






Figure 9 C4-2B cells with decreasing concentrations of FLIPI, the control for this assay is 0 µM of FLIPi with increasing concentrations, thereafter, 
initially starting at 100 µM. Crystal violet stain was used to visualise cell growth after 7 days of treatment. Each cell line was repeated 3 times, 























PC3 is a prostate cell line derived from bone metastases of a male diagnosed with 
grade IV prostatic adenocarcinoma. It is regarded as being highly metastatic and are 
androgen independent. It is regarded as being slightly sensitive to TRAIL. FLIPi 0 µM 
as expected had no effect on apoptosis. However, there were significant cytotoxic 
effects seen in FLIPi 100 µM, boasting an approximate cell survival reduction of an 
estimated 60% compared to the 0 µM. There were little cytotoxic effects seen in lower 
concentrations up of FLIPi. With very little cytotoxic effect seen in FLIPi 3.1 µM, 
comparatively to the 0 µM there was a small reduction of approximately 10%. 
Comparatively to the 0 µM control the FLIPi showed cytotoxic effects even at lower 
concentration of 3.12 µM that increased in a dose-dependent manner. In summary 












Figure 10 Cell survival measured in PC3 cells pre-treated with decreasing FLIPi concentrations, the control for this assay is 0 µM of FLIPi with 
increasing concentrations thereafter. Cells stained with crystal violet to visualise after 7 days of treatment. Each cell line was repeated 3 times, 























The DU145 cell line is a human prostate cancer cell line derived from a brain carcinoma 
in a male, it is described as not hormone sensitive and so is androgen independent. It 
is thought that it is moderately sensitive to TRAIL. However, there were cytotoxic 
effects seen in FLIPi 100 µM, boasting an approximate cell survival reduction of an 
estimated 30% compared to the 0 µM. There was very little cytotoxic effects seen in 
lower concentrations up of FLIPi. With no cytotoxic effect seen in FLIPi 3.1 µM, 
comparatively to the 0 µM there was actually a small increase of approximately 1% 
suggesting an error suggesting a repeat may be useful. This did not impact the 
outcome of the experiment. In summary, there is only cytotoxic effects seen at higher 


















Figure 11 Cell survival measured in DU145 cells pre-treated with decreasing FLIPi concentrations, the control for this assay is 0 µM of FLIPi 
with increasing concentrations thereafter. Cells stained with crystal violet to visualise after 7 days of treatment. Each cell line was repeated 3 






The breast cancer cell line MDA-MB-231 was used, as it is one of the most commonly 
diagnosed cancers. It was derived from a female metastatic mammary 
adenocarcinoma. It is a very aggressive cancer and is triple negative as it has an 
absence of lacking ER and PR expression and HER2 amplification. This cell line is 
regarded as very sensitive to TRAIL. Overall, there was no significant apoptosis seen 
with the FLIPi as a single treatment in the MDA-MB-231 cell line. There is a very slight 
increase in the apoptotic percentage with 100 µM of FLIPi in comparison to 0 µM, with 
an approximate 20% reduction cell survival. The biggest reduction on cell growth was 
observed at 50 µM FLIPi showing a cell survival rate of 63%. At lower concentrations 
there were much lower cytotoxic effects seen. In summary, there were some cytotoxic 
effects seen, but knowing this is a TRAIL sensitive cell line, repeats would be 






Figure 12 cell survival measured in MDA-MB-231 cells treated with decreasing FLIPi concentrations, the control for this assay is 0 µM 
of FLIPi with increasing concentrations thereafter. Cells stained with crystal violet to visualise after 7 days of treatment. Each cell line 
























Pancreatic cell line PancTu1 was used this was cancerous epithelial tissue from a male 
pancreas. This cell line is known to react poorly to TRAIL and so the expectation was 
that there would be limited cytotoxic effects seen. There were significant cytotoxic 
effects seen at 100 mM with an approximate 60% reduction in cell survival compared 
to 0 mM. Compared to the untreated control the FLIPi showed cytotoxic effects even 
at the lower concentrations of that increased in a dose-dependent manner starting to 
show little to no effect from 6.3 mM onwards. In summery there were some cytotoxic 























Figure 13 cell survival measured in PancTu1 cells treated with decreasing FLIPi concentrations, the control for this assay is 0 µM of FLIPi with 
increasing concentrations thereafter. Cells stained with crystal violet to visualise after 7 days of treatment. Each cell line was repeated 3 times, 







3.2 Apoptosis induction after cFLIP inhibitor treatment  
Next, we measured apoptosis in cells treated with FLIPi. For this we used a DNA 
hypodiploidy assay also known as Nicoletti assay (Riccardi and Nicoletti, 2006). In this 
methods, harvested cells are made permanent for the DNA dye PI. The PI enters the 
cells and nucleus where it stains the DNA. The emitted fluorescent signal can be 
measured and quantified by flow cytometry. Apoptotic cells fragment their DNA, which 
leads to a reduced signal and the appearance of a sub-G1 peak in the flow cytometric 
histograms. The percentage of cells that appeared in the sub-G1 peak were quantified 
and defined as apoptotic.  
When we tested PC3 cells for apoptosis induction, there was no significant apoptosis 
observed (Figure 14). All measured apoptosis levels were below 5% and can be 
considered as background and any fluctuations at and around this level as normal 
measuring variability. In conclusion, the FLIPi did not cause any apoptosis at the 































Figure 14 Apoptosis measured in PC3 cells treated with decreasing concentrations of FLIPi, the control for this assay is 0 µM of FLIPi with 
increasing concentrations thereafter. Cells treated with Nicoletti buffer and measured using flow cytometry, measured 48 hours after treatment 

























Figure 15 Apoptosis measured in LNCaP cells treated with decreasing concentrations of FLIPi, the control for this assay is 0 µM of FLIPi with 
increasing concentrations thereafter. Cells treated with Nicoletti buffer and measured using flow cytometry, measured 48 hours after treatment 
with FLIPi. This cell line was repeated 4 times with each concentration being tested 3 times with an average taken. 
 
When tested apoptosis measurements in LNCaP cells did not reveal any significant 
apoptosis induction (Figure 15). There is possibly some increased apoptosis occurring 
at 100 µM of FLIPi but even that is at a very low level. All apoptosis rates were below 
10% this could be considered as normally occurring apoptotic activity with variations 
between concentration being due to measuring viability. In conclusion FLIPi did not 


















HCT116 cells were tested for apoptotic induction and there was no significant apoptotic 
activity seen in HCT116 cells treated with FLIPi. All apoptosis levels were below 5% 
which can be credited to normally occurring apoptotic activity and variations that occur 













Figure 16 Apoptosis measured in HCT116 cells treated with decreasing concentrations of FLIPi, the control for this assay is 0 µM of FLIPi with 
increasing concentrations thereafter. Cells treated with Nicoletti buffer and measured using flow cytometry, measured 48 hours after treatment 














































Figure 17 Apoptosis measured in MDA-MB-231 A cells treated with 0 (control) and 50 µM  of FLIPi. Cells treated with Nicoletti buffer and 
measured using flow cytometry, measured 48 hours after treatment with FLIPi. Each concentration was tested 3 times each and an average 
taken for use in analysis. 
 
 
Similarly, in MDA-MB-231 cells there is no significant apoptosis induction after 
treatment with FLIPi of 50 µM. When tested for apoptotic induced activity, MDA-MB-
231 showed no significant activity occurring (figure 17). All apoptosis levels were below 
4% and can be considered as background/normal activity. Variations between the 
concentrations are due to normal variability in the measuring process. In summary 
















When testing for apoptosis induction C2-4B showed no significant apoptosis observed 
at either concentration (Figure 18). Both concentrations have apoptotic levels of below 
2%. This can be attributed to normal cell functions. In summary FLIPi did not induce 























Figure 18 Apoptosis measured in C4-2B cells treated with 0 (control) and 50 µM of FLIPi. Cells treated with Nicoletti buffer and measured 
using flow cytometry, measured 48 hours after treatment with FLIPi. Each concentration was tested 3 times each and an average taken for 









3.3 Combination treatments of FLIP inhibitor and TRAIL 
Finally, we analysed the effects of the FLIPi and TRAIL on several different cell lines. 
As cFLIP is known to be a cellular inhibitor of caspase-8, the initiator caspase in 
extrinsic and TRAIL induced apoptosis, we hypothesised that the FLIPi could sensitise 
cells to the effects of TRAIL. 
 
Firstly, prostate cancer cell line C4-2B was tested the in a combination approach. C4-
2B cells shows relative r TRAIL resistance or in other words TRAIL only triggers a 
limited level of cell death (around 8%). However, when C4-2B cells were co-treated 
with FLIPi there is a sensitisation effect with more than double the apoptosis seen with 
the combined treatment compared to the single TRAIL treatment. Untreated and FLIPi 
treated cells showed no biologically significant levels of apoptosis. Thus, the FLIPi 
appeared to be able to block the apoptosis-inhibitory effects of cFLIP and sensitise C4-















Figure 19 Apoptosis measured in C4-2B cells treated with 0 (the control) and 50 µM of FLIPi. Treated with recombinant TRAIL singularly and 
then co-treated with TRAIL 1 ng/mL and 50 µM FLIPi. Cells treated with Nicoletti buffer and measured using flow cytometry, measured 48 hours 



















Next LNCaP prostate cell line was tested, treated with a combination approach. There 
was a limited amount of apoptosis induced and shows a relative TRAIL resistance only 
inducing approximately 8.5% of apoptosis at most (figure 20). When co-treated with 
TRAIL there was a slightly increased amount of apoptosis triggered, at approximately 
9% of apoptosis at the same concentration. Overall, there was no biologically 
significant apoptosis seen with FLIPi as a single treatment or when co-treated with 


















Figure 20 Apoptosis measured in LNCaP cells treated with varying concentrations of FLIPi, the control for this assay is 0 µM of FLIPi with 
increasing concentrations thereafter. Then treated with recombinant TRAIL and FLIPi as a co-treatment, with recombinant TRAIL at 5 ng/ml. 
Cells treated with Nicoletti buffer and measured using flow cytometry, measured 48 hours after treatment with FLIPi. Each concentration was 



























Then HCT116 cells were tested. When using a combined treatment approach a high 
amount of apoptosis is triggered; approximately 67%. Comparatively, FLIPi as a 
singular treatment shows no significant apoptosis triggered and shows this cell line as 
being relatively TRAIL resistant. TRAIL as a singular treatment induces an estimated 
half of the apoptosis compared to that of the combined treatment. Overall FLIPi 
appeared to be able to sensitise cells to TRAIL by blocking the effects of cFLIP for 

























Figure 21 Apoptosis measured in HCT116 cells treated with 0 (control) and 50 µM of FLIPi. Treated with recombinant TRAIL singularly and then 
co-treated with TRAIL 50 µM and FLIPi, with recombinant TRAIL 5 ng/ml. Cells treated with Nicoletti buffer and measured using flow cytometry, 










Lastly MDA-MB-231 breast cancer cell line was tested using a combination treatment 
approach. MDA-MB-231 shows a relative sensitivity to TRAIL with approximately 40% 
cell death being triggered (figure 22). However, when MDA-MB-231 cells were co-
treated with FLIPi there was sensitisation seen at an estimated 30%. It appears FLIPi 
can block the inhibitory effects of cFLIP to sensitise the cells for TRAIL induced 
apoptosis. Overall, there was sensitisation seen when using FLIPi and TRAIL together. 
However, as MDA-MB-231 is known to already be sensitive to TRAIL induced 
apoptosis, more apoptosis would be expected to be induced. Due to this more repeats 





In conclusion MDA-MB-231, HCT116 and C4-2B cell lines are sensitised to TRAIL 

























Figure 22 Apoptosis measured in MDA-MB-231 cells treated with 0 (control) and 50 µM of FLIPi. Treated with recombinant TRAIL singularly and 
then co-treated with TRAIL and FLIPi, recombinant TRAIL 5 ng/ml. Cells treated with Nicoletti buffer and measured using flow cytometry, measured 











This project was undertaken to ascertain the ability and efficiency of a novel small 
chemical FLIPi to sensitise cancer cells to TRAIL. In order to do this, FLIPi was used 
singularly and in combination with TRAIL. 
 Apoptosis and survival of the cancer cells after treatment was measured using crystal 
violet and DNA hypodiploidy (Nicoletti) assays. Overall, the effects of the FLIPi were 
mixed, with some cancer cells responding to inhibitor/TRAIL combinations while others 
did not. Understanding the reasons will be a question to be addressed in the future. 
The HCT116 cell line is known to be sensitive to TRAIL. Crystal violet assays show no 
significant effect of cell survival after treatment with varying concentrations of FLIPi. 
However, there was an approximate 50% reduction in cell survival at 100 µM compared 
to that of 0 µM. Preliminary Nicoletti results also support this conclusion, although there 
is some apoptotic activity seen and the most seen at 6.25 µM.  There is very little 
apoptosis seen at 0 µM and 50 µM. There is a small amount of apoptotic activity seen 
when treated with 5 ng/ml of recombinant TRAIL, however the largest and notable 
amount of apoptosis occurred with a combination treatment of TRAIL and FLIPi. 
Suggesting the addition of FLIPi aids in sensitising the cells and enabling the action of 
TRAIL. 
C4-2B cell line showed no significant change in cell survival observed within the crystal 
violet assay. Nicoletti assays showed no increased apoptosis when treated with 50 µM 





when treated singularly with FLIPi as there was no significant increase in apoptosis. 
Similarly, there was only a small increase when cells were treated with 5 ng/ml of 
recombinant TRAIL. However. When treated with a combination there was a significant 
increase apoptotic percentage.  
LNCaP cells showed no significant effects, although there was a low cell survival seen 
with the highest single concentration of FLIPi used – 100 µM. Nicoletti results also 
corroborate the limited effects seen with FLIPi. When treated with TRAIL and FLIPi in 
combination there was also no significant effects observed. This suggests a resistance 
to TRAIL and no sensitisation being achieved. 
Prostate cancer cell line PC3 saw a slight reduction in cell survival at concentrations 
of 100 µM and 50 µM however overall, there is no sensitisation evident. Similarly, there 
was no significant effect seen with prostate cancer cell line DU145.  
Deletions in this cell line such as PTEN- a known driver of tumorigenesis- could 
suggest these mutations would lend an advantage of survival to cancer cells. This 
could help evade cell death resulting in a resistance and/or seeing treatments be 
ineffective. 
The MDA-MB-231 cell line was treated singularly with varying concentrations of FLIPI 
shows no significant effect on cell survival. However, there was significant apoptosis 
seen with initial Nicoletti experiments. There was a reduction in the amount of 
apoptosis observed when a combination of FLIPi and recombinant TRAIL was 





 Little sensitisation is seen in the DU145 cells line. Previous research suggests that 
when DU145 cells lose the wild type p53 allele, tumour progression, resistance to 
traditional therapies and a worsened prognosis are the consequences. This could 
suggest that mutation in this gene could lead to a lack tumour suppression and reaction 
to treatment.  
4.1 cFLIP action in the apoptosis pathway 
4.1.1 FLIP action summary 
FLIP is most known for the inhibitory characteristics is possesses on the death 
receptor-mediated apoptotic cascade. Once the ligand has bound to the receptor, with 
respect to TRAIL this would be death receptor 4 or 5 the death inducing signalling 
complex is formed (Wajant, 2019) . This complex enlists FADD which is an adaptor 
protein and also engages caspase-8 at the cytosolic domain of the receptor (Roth and 
Reed, 2004). Clustering of pro caspase-8 zymogen occurs around aggravated 
receptor complexes which forms the bases of the induced proximity mechanism 
(Sprick et al., 2000). This mechanism causes caspase-8 to be cleaved into p43 and 
p10 fragments, subsequently p43 is broken down into p18 which is the active caspase 
unit. However, when FLIP is present death effector homotypic interactions are formed 
between FADD and FLIP molecules. This causes proteolytic cleavage of FLIP and 
recruitment into the DISC. The p43 fragment remains in the DISC bound to the 
previously formed complex. This means that FLIP proteins are dominant negative 





4.1.2 Functions of FLIP in forming the Ripoptosome and the role in 
Necroptosis 
Cells can initiate caspase-8 activation independent of extrinsic death ligand to death 
receptor interactions, in very specific conditions. A protein - Receptor interacting 
protein kinase 1 (RIPK1) – was found to interact with tumour necrosis factor receptor 
1 signaling complex. This protein is imperative in cell survival, apoptosis and 
necroptosis regulation. It is regulated through ubiquitylation and phosphorylation 
processes, with cellular inhibitors of apoptosis (cIAP) are found to ubiquitylate RIPK1. 
When cellular inhibitors of apoptosis were examined in order to ascertain whether 
elimination would affect cell death processes. It was found that spontaneous death 
receptor independent formation of ripoptosome, a complex containing RIPK1, FADD, 
caspase-8 and cFLIP. Procaspase-8 is integrated into the ripoptosome and processed 
via heterodimerisation which results in the cleavage and activation of RIPK1 thus 
degrading the ripoptosome. This results in caspase-8 mediated apoptosis being 
implemented exclusively. However, cFLIP can play a key role in this process. When 
cFLIP in integrated into the ripoptosome, heterodimerisation activates procaspase-8. 
This can cleave substrates and the activate RIPK1, although once the ripoptosome is 
disassembled procaspase-8 become inactivate again. Consequently, this means 
cellular survival is achieved by blocking apoptosis (Tsuchiya et al., 2015). 
Necroptosis is initiated when cFLIP promotes the assembly of the ripoptosome, 
however cannot activate procaspase-8. This is physiologically regulated by RIPK1, 





distinguishing this process from unintentional necrosis (Pasparakis and 
Vandenabeele, 2015). Other death-inducing protein complexes are formed with the 
involvement of cFLIP such as apoptotic inhibitory complex. The complex is made up 
of DR5-, FADD-, Caspase-8, and FLIPL and has currently been found in MCF-7 breast 
cancer cells (Day et al., 2008). 
4.2 Functions of FLIP 
It has been suggested overexpression of cFLIP can lead to apoptosis rather than inhibit 
it.  This was thought to be due to clustering of large- non-physiologic- amounts of FLIP 
protein, resulting in activation of caspase-8. However, at lower (physiologic) 
expression, cFLIP actually performs a protective role, and death receptor induced 
apoptosis is inhibited (Chang et al., 2002). FLIP binds to FADD which interferes with 
TNF-α, Fas-L, and TRAIL-induced signalling pathways and current research suggests 
that overall cFLIP has anti-apoptotic characteristics in cancer cells. It is thought that 
the discord surrounding cFLIP function is due to the varying forms/structure cFLIP can 
have. cFLIPs has been implicated in TRAIL induced DISC formation and consequent 
apoptosis and have been seen to inhibit this pathway. cFLIPL is also involved in these 
processes but also when expressed in higher levels it inhibits Fas-induced activation 
of caspase-8. Oppositely when the expression is low it can also mean caspase-8 
activation is boosted. It is thought that the long form of cFLIP forms heterodimeric 
enzyme molecules with key features of substrate specificity and having extremely 
similar catalytic activity to that of caspase-8 homodimers. This is despite cFLIP being 





via AKT, ERK, and NF- κB signalling pathways through acting as an effector. NF-κB 
and ERK signalling pathways can be activated by binding to the specific adaptor 
proteins specific to each pathway due to a high level of expression of FLIPL (Safa et 
al., 2008).  
 
4.3 Levels of cytoplasmic FLIP and TRAIL sensitivity 
Evidence would suggest that MDA-MB-231 breast cancer cell should be sensitive to 
TRAIL (Di et al., 2013). This cell line presents a mesenchymal like morphology, and 
research suggests that this leaves the cells vulnerable to TRAIL and the pro-apoptotic 
effects. (Huang et al., 2020). 
Investigating the extrinsic pathway shows that for cFLIP to cause inhibition it must be 
able to impede the caspase-8 recruitment. cFLIP would have to be present in the 
cytoplasmic compartment of the cell so that there can be interactions with the DISC. 
Wnt signalling has been associated with mesenchymal-like cells and consequent 
increased signalling. Due to this it could be suggested that sub-cellular 
compartmentalisation of cFLIP would be the biggest influencing factor in shaping 
TRAIL sensitivity (French et al., 2015).  Levels of cFLIP in the cytoplasm was found to 
be reduced in this specific cell line and in that of similar tumours. Thus, supporting the 
theory of reduced cFLIP levels leading to increased sensitivity it is thought that this cell 





4.4 FLIP protective properties evidenced by MCF7 cell line 
Upon investigation over high levels cFLIP had a protective action. It was seen that 
within MCF-7 cell line which is cancer stem/progenitor line is protected from TRAIL 
due to overexpression of cytoplasmic cFLIP expression. Conversely it was found that 
nuclear FLIP did not possess this protective effect, and if fact both types have been 
implicated in breast cancer stem cell maintenance mechanisms. This is because raised 
levels of both types of cFLIP were found to lead to a significant increase in 
tumourspheres forming but have differing functions in relation to apoptosis inhibition 
(French et al., 2015). 
4.5 FLIP and HCT116 cell line 
It has been well established that over-expression of cFLIP is linked to resistance in 
colorectal cancer. This resistance applies to standard treatments such as 5FU and 
oxaliplatin, once again highlighting why ongoing research into cFLIP inhibitors is so 
vital. It also extends to therapies that target apoptotic pathways. cFLIP prevents cell 
death when involved with both monovalent and bivalent inhibitor of apoptosis protein 
(IAP) (Humphreys et al., 2018). 
Wilson et al. (2007) also showed HCT116 cells as being sensitive to TRAIL, and it is 
thought that relative sensitivity levels is concurrent to the amount of death receptors 
on the cell surface.  It was found that that cFLIPL was a promoter for the first cleavage 





and p18 subunits, resulting in obstructing caspase-8–mediated apoptosis (Micheau et 
al., 2002).  
It has also been found that when cFLIP is downregulated, cell lines can be sensitised 
to TRAIL, with results showing a synergy; more apoptosis was induced with down 
regulation of cFLIP and cell lines being treated with traditional chemotherapies (Fulda 
et al., 2000). It is theorised that colorectal cancer cells form DISCs that contain cFLIP 
and that these regulate the activity of antiapoptotic signalling pathways where there is 
no ligand binding activation. However, when cFLIP is down-regulated or silenced, it 
results in these DISCs activating caspase-8 and consequently inducing apoptosis. 
cFLIPL was found to interact with DR5 in a TRAIL and FADD-independent manner and 
if this interaction was interrupted it caused in TRAIL independent apoptosis to occur 
(Jin et al., 2004). FLIPL is thought to - in respect to D5 - inhibit ligand-independent 
recruitment of FADD and caspase-8. This would suggest that cFLIPL inhibits ligand-
independent recruitment of FADD and caspase-8 in to the DR5 DISC. therefore down-
regulating cFLIPL can induces apoptosis by this process (Wilson et al., 2007). Therefore, 
it could be suggested that inhibiting cFLIP could also have this apoptosis induing effect. 
4.6 cFLIP and LNCaP cell line 
The results of this research did not show sensitisation to TRAIL with the LNCaP cell 
line. However, research showed that high levels of cFLIP expression in this cell line 
lead to apoptotic inhibition via acceleration of androgen independence (Valnet-Rabier 





 Wilson et al. (2008) and Zhang et al. (2004) also found that LNCaP cell line was poorly 
sensitive to TRAIL. It was also found that when cFLIP was over expressed the pro-
apoptotic initiation by activation on caspase -8, was inhibited. Down regulation of cFLIP 
was also found to sensitise cells when TRAIL was administered (White et al., 2006). 
FLIP was found to be higher in LNCaP cells than cells that are known to be TRAIL 
sensitive even after 24 hours of TRAIL treatment. 
Comparatively, in PC3 cells FLIP and mRNA levels were found to be lower in cells that 
are TRAIL-sensitive after TRAIL treatment. This suggests a strong connection 
between TRAIL sensitivity of cFLIP expression (Zhang et al., 2004). This could infer a 
higher level of cFLIP in this cell line and thus why it is not a TRAIL sensitive. 
Also as previously mentioned, tumour suppressor genes could be mutated in this cell 
line. However, due to the lack of knowledge on the functional regions of some of these 
specific genes such as menin the full effect on cancer behaviour is hard to determine 
(Seim et al., 2017). 
4.7 Further strategies to use FLIP as a cancer therapy  
Due to FLIP being both proapoptotic and antiapoptotic in nature, these properties can 
be manipulated in order to sensitise cells to TRAIL overcoming the current obstacle of 
resistance (Mathas et al., 2004). Small interfering RNAs (siRNA) have been seen to 
knockdown the expression of cFLIP in several cell lines such as H460 lung carcinoma 
cells (Sharp et al., 2005). This research showed that the knockdown in expression of 





New therapies are used in order to reach apoptosis to be triggered at a lower threshold 
and therefore be a more effective treatment. Recent research used small interfering 
RNAs (siRNAs) that downregulated the expression of cFLIP. As previously discussed, 
this could lead to more sensitisation to TRAIL and therefore overcoming the resistance 
problem. 
Due to the significant similarities in caspase-8 and cFLIP structure, small molecules 
that prevent cFLIP from being recruited into the DISC will also prevent caspase-8 from 
moving into the DISC. This would result in apoptosis being inhibited, so research into 
this avenue of exploration could be useful for expanding treatments (Safa, 2012). 
Inhibiting cFLIP is thought to be difficult as there is no structure where small molecule 
ligands can bind. This is due to the highly conserved properties of the DED which 
predominately use homotypic binding. However, in the last few years a couple of FLIPi 
have been developed, one of which was tested here. If such inhibitors would not have 
been feasible  the inhibitor tested would not have worked at all as the DEDs would be 
similar in all cell lines. (Safa et al., 2008). 
4.8 Summarising remarks 
There were some promising results, HCT116 cell line was known to be sensitive to 
TRAIL. With some suggestions this is due to the role cFLIP plays in regulating ligand 
binding induced apoptosis and the amount of receptors present. When downregulated 
or silenced enhanced apoptotic induction by TRAIL is seen suggesting great promise 





MDA-MB-231 saw some apoptosis with Nicoletti assays, with a reduction in the amount 
of apoptosis observed when treated with a combination of FLIPi and recombinant 
TRAIL. This suggests a TRAIL resistance evidenced by an increase in apoptosis- 
compared to a single treatment of FLIPi- when cFLIP was administered. Overall, there 
is a promising future of future research with this inhibitor. Previously mentioned 
association with mutations with p53 could aid in understanding why this is such a hard 
to treat and aggressive cell line. 
Some sensitisation was seen in the pancreatic cell line; however, this would need more 
repeats due to a lack of time. Due to the breakpoints seen within chromosome 8 with 
pancreatic cancers, it could be worth exploring the NRG1 gene that is mutated as it 
could be an oncogene/tumour suppressor and targeting it could be a good therapeutic 
target. 
However, there was not sensitisation seen in all cell lines. PC3 cell line is thought to 
be moderately sensitive TRAIL. However, cytotoxic effects were seen during cell 
survival assays, but no further evidence was seen as a result of measuring apoptosis 
after treatment. DU145 cells are thought to be moderately sensitive to TRAIL however, 
there was no sensitisation seen in the results. C4-2B and LNCaP cell lines also showed 









This vein of research -finding a novel therapeutic agent- is important as it could 
overcome the necessity to use traditional chemotherapies that are not as damaging to 
healthy cells without compromising on the quality of cancer cell destruction. This would 
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